Company intelligence / Profile preview

Better Pulse

Ownership: Private
Development stage: Preclinical

Overview

Better Pulse is developing a sustainable, allergen-free plant protein concentrate from black-eyed peas using advanced breeding and CRISPR-Cas technologies. The company has secured $400,000 in pre-seed funding from the Israel Innovation Authority and participated in leading accelerator programs. No clinical results as it is not a pharmaceutical company.

Therapeutic areas: Other
Modalities: Protein (plant-derived)CRISPR-based crop improvementProtein concentrate extraction technology
Industry: Food & Nutrition

Partnerships

Participated in Dan LaunchPad powered by Tel Aviv UniversityVIB Biotope accelerator program participant

Beyond the preview

Go deeper on Better Pulse.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Better Pulse.

Explore the full profile